Euthyroid Sick Syndrome

Euthyroid Sick Syndrome (ESS), also known as non-thyroidal illness syndrome (NTIS), is a complex endocrine adaptation observed in critically ill or systemically diseased patients, characterized by alterations in circulating thyroid hormone concentrations in the absence of intrinsic thyroid gland dysfunction. In veterinary medicine, ESS is recognized in both dogs and cats with a variety of severe systemic illnesses, including sepsis, trauma, neoplasia, hepatic disease, renal failure, and cardiac disease. The hallmark biochemical findings include decreased serum total thyroxine (TT4) and free thyroxine (fT4) concentrations, often with normal or low thyroid-stimulating hormone (TSH) levels, and in some cases, decreased triiodothyronine (T3) with increased reverse T3 (rT3). The condition reflects a homeostatic response to reduce metabolic rate and conserve energy during critical illness, rather than a primary thyroid disorder. It is essential to differentiate ESS from true hypothyroidism, as inappropriate thyroid hormone supplementation in ESS can be detrimental. The diagnosis relies on recognizing the clinical context of systemic illness and interpreting thyroid function tests in light of the patient's overall condition.

The etiology of ESS is multifactorial and directly linked to the severity and duration of the underlying systemic illness. Common causes include: (1) Infectious diseases: bacterial sepsis, viral infections (e.g., canine distemper, feline infectious peritonitis), protozoal infections (e.g., babesiosis, leishmaniasis), and fungal infections. (2) Inflammatory conditions: pancreatitis, inflammatory bowel disease, immune-mediated diseases (e.g., immune-mediated hemolytic anemia, polyarthritis). (3) Neoplastic diseases: lymphoma, mast cell tumors, and other malignancies. (4) Metabolic disorders: diabetes mellitus, hyperadrenocorticism, and hepatic insufficiency. (5) Organ dysfunction: chronic kidney disease, congestive heart failure, and respiratory disease. (6) Trauma and surgery: severe tissue injury, burns, and major surgical procedures. (7) Nutritional deficiencies: malnutrition, starvation, and protein-losing enteropathy. (8) Pharmacological agents: glucocorticoids, phenobarbital, sulfonamides, and nonsteroidal anti-inflammatory drugs can suppress thyroid function. The underlying mechanisms involve cytokine-mediated inhibition of the hypothalamic-pituitary-thyroid axis, altered thyroid hormone binding to serum proteins, decreased tissue uptake of thyroid hormones, and impaired peripheral conversion of T4 to T3 due to reduced activity of type 1 and type 2 deiodinases, with increased activity of type 3 deiodinase leading to rT3 accumulation.

ESS is a common finding in critically ill dogs and cats, with prevalence rates varying depending on the population studied. In dogs, ESS has been reported in up to 60-70% of patients admitted to intensive care units, with higher incidence in those with sepsis, systemic inflammatory response syndrome (SIRS), or multiple organ dysfunction. In cats, ESS is frequently observed in those with chronic kidney disease, hyperthyroidism (concurrent non-thyroidal illness), and inflammatory bowel disease. There is no clear breed or sex predisposition, but age may play a role, as older animals are more likely to have concurrent diseases. The condition is more prevalent in patients with prolonged hospitalization and severe illness. Geographic variation may reflect regional infectious disease prevalence, such as leishmaniasis in Mediterranean areas. ESS is not a primary thyroid disease, so it does not have a genetic basis, but the underlying diseases may have breed predispositions (e.g., Doberman Pinschers for dilated cardiomyopathy, which can lead to ESS).

The pathophysiology of ESS is complex and involves multiple mechanisms at the hypothalamic, pituitary, thyroid, and peripheral tissue levels. During critical illness, pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6) are released. These cytokines inhibit the secretion of thyrotropin-releasing hormone (TRH) from the hypothalamus and thyroid-stimulating hormone (TSH) from the anterior pituitary, leading to reduced thyroidal stimulation. Additionally, cytokines impair the synthesis and secretion of thyroid hormones from the thyroid gland itself. In the periphery, there is decreased activity of type 1 deiodinase (D1) in the liver and kidney, which converts T4 to T3, and type 2 deiodinase (D2) in other tissues, resulting in lower T3 concentrations. Conversely, type 3 deiodinase (D3) activity is increased, converting T4 to reverse T3 (rT3), which is biologically inactive. This leads to an elevated rT3/T3 ratio. Furthermore, systemic illness can cause alterations in thyroid hormone binding proteins, such as decreased albumin and transthyretin, and increased free fatty acids that displace T4 from binding proteins, leading to altered total hormone measurements. Tissue uptake of thyroid hormones may also be impaired due to downregulation of thyroid hormone transporters. The net effect is a state of low circulating thyroid hormone levels, which is thought to be an adaptive mechanism to reduce metabolic rate and preserve energy during illness. However, in some cases, the severity of the illness may overwhelm the adaptive response, and the low thyroid hormone state may contribute to organ dysfunction.

Predisposing factors for ESS include any condition that leads to systemic inflammation, critical illness, or severe metabolic stress. Intrinsic factors include age (geriatric patients are more susceptible), genetic predisposition to certain diseases (e.g., breed-specific immune-mediated disorders), and pre-existing endocrine or metabolic diseases such as diabetes mellitus or hyperadrenocorticism. Extrinsic factors include poor nutritional status, prolonged fasting, and the use of certain medications, particularly glucocorticoids, which are known to suppress thyroid function. Concurrent infections, especially those causing sepsis, are significant triggers. Hospitalization itself, with associated stress and interventions, can contribute to the development of ESS. Additionally, surgical procedures and trauma are common predisposing events. In cats, chronic kidney disease is a major predisposing factor, while in dogs, neoplasia and cardiac disease are frequent underlying causes.

The clinical signs of ESS are primarily those of the underlying systemic illness, as ESS itself does not cause specific clinical signs. However, some patients may exhibit non-specific signs such as lethargy, weakness, anorexia, and weight loss, which are common in critical illness. In dogs and cats with ESS, physical examination may reveal signs related to the primary disease, such as fever, dehydration, tachycardia or bradycardia, tachypnea, pale mucous membranes, or icterus. There are no specific dermatological or neurological signs attributable to ESS. In chronic cases, some animals may show poor hair coat or alopecia, but these are more likely due to the underlying disease or malnutrition. It is crucial to recognize that ESS is a biochemical diagnosis, and clinical signs should be attributed to the primary illness rather than to hypothyroidism. In rare cases, if the underlying illness is prolonged and severe, the low thyroid hormone state may exacerbate metabolic derangements, but this is not well-defined in veterinary medicine.

The primary differential diagnosis for ESS is primary hypothyroidism, which is common in dogs but rare in cats. Key features to differentiate include: (1) Primary hypothyroidism: typically presents with bilateral non-pruritic alopecia, weight gain, lethargy, and bradycardia. Laboratory findings include low TT4, low fT4, and elevated TSH (in dogs). In ESS, TSH is usually normal or low. (2) Secondary hypothyroidism (pituitary disease): rare, associated with other pituitary hormone deficiencies, and TSH is low. (3) Hyperthyroidism in cats: can have concurrent non-thyroidal illness, but thyroid hormone levels are elevated, not decreased. (4) Iatrogenic hypothyroidism: due to thyroidectomy or radioactive iodine treatment, history is key. (5) Euthyroid dogs with low TT4 due to autoantibodies: anti-T4 antibodies can interfere with assays, but fT4 by equilibrium dialysis is normal. (6) Non-thyroidal illness with low T3 only: some patients have isolated low T3, which is less severe than full ESS. (7) Drug-induced thyroid suppression: glucocorticoids, phenobarbital, sulfonamides, and NSAIDs can lower thyroid hormone levels; history of drug administration is crucial. (8) Malnutrition or starvation: can cause low T3 syndrome, but T4 may be normal. (9) Chronic renal failure: can cause low T4 and fT4, but TSH is usually normal. (10) Hepatic disease: can cause low T4 due to decreased binding proteins. Definitive differentiation requires a thorough history, physical examination, and comprehensive thyroid panel including TSH and fT4 by equilibrium dialysis, as well as assessment of the underlying disease.

The diagnostic approach to ESS involves a stepwise process: (1) Recognize the clinical context: ESS should be suspected in any critically ill patient with systemic disease. (2) Perform a complete blood count, serum biochemistry panel, and urinalysis to identify the underlying disease. (3) If thyroid function tests are indicated (e.g., to rule out hypothyroidism), measure serum TT4, fT4 by equilibrium dialysis, and TSH. (4) Interpret results: In ESS, TT4 is typically low, fT4 may be low or normal, and TSH is normal or low. In primary hypothyroidism, TT4 is low, fT4 is low, and TSH is elevated (in dogs). (5) If results are equivocal, consider additional tests such as T3, rT3, or thyroid autoantibodies, but these are not routinely recommended. (6) Treat the underlying disease and re-evaluate thyroid function after recovery. (7) If hypothyroidism is still suspected after resolution of the illness, repeat thyroid testing. (8) In cats, be cautious: hyperthyroidism can coexist with non-thyroidal illness, and thyroid hormone levels may be misleading. (9) Consider thyroid scintigraphy if available, but it is rarely needed. (10) Always interpret thyroid tests in light of the patient's clinical status and drug history.

Hematology: Non-specific changes related to the underlying disease, such as leukocytosis or leukopenia, anemia, or thrombocytopenia. Serum Biochemistry: May show elevations in liver enzymes (ALT, ALP), azotemia, hyperglycemia or hypoglycemia, electrolyte imbalances, and altered protein levels (hypoalbuminemia). Urinalysis: May reveal proteinuria, casts, or evidence of urinary tract infection. Blood Gas Analysis: May show metabolic acidosis or respiratory alkalosis depending on the underlying condition. Specific Biomarkers: Inflammatory markers such as C-reactive protein (CRP) may be elevated. Endocrinological assays: The hallmark is decreased serum TT4 and fT4 (by equilibrium dialysis) with normal or low TSH. T3 may be low, and rT3 may be elevated, but these are not routinely measured. In dogs, a TSH concentration >0.6 ng/mL is suggestive of hypothyroidism, but in ESS, TSH is typically within the normal range or suppressed. In cats, TSH is less reliable, and fT4 by equilibrium dialysis is preferred. Additionally, thyroid autoantibodies (TgAA, T4AA, T3AA) may be present in some cases of hypothyroidism but are not specific for ESS.

Imaging findings are those of the underlying disease. Thoracic radiography may reveal pulmonary infiltrates, cardiomegaly, or masses. Abdominal ultrasonography may show hepatomegaly, splenomegaly, renal changes, or pancreatic abnormalities. Echocardiography may be indicated if cardiac disease is suspected. Computed tomography (CT) or magnetic resonance imaging (MRI) may be used for specific conditions such as neoplasia or pituitary lesions. There are no specific imaging features of ESS itself.

Cytology and histopathology are not used to diagnose ESS directly. However, if a biopsy is performed for the underlying disease, histopathological findings will reflect that disease. For example, liver biopsy may show inflammation or neoplasia, and kidney biopsy may show chronic interstitial nephritis. Thyroid gland histopathology in ESS is typically normal, with no evidence of lymphocytic infiltration or atrophy, which helps differentiate from primary hypothyroidism.

The primary treatment for ESS is to address the underlying systemic illness. There is no specific therapy for ESS itself, and thyroid hormone supplementation is not recommended, as it may be harmful. Supportive care is essential, including fluid therapy, nutritional support, and management of organ dysfunction. In critically ill patients, intensive monitoring and treatment of the primary disease are paramount. If the patient is receiving medications that suppress thyroid function (e.g., glucocorticoids), these should be tapered or discontinued if possible. In some cases, treatment of the underlying disease leads to normalization of thyroid hormone levels. There is no evidence to support the use of thyroid hormone replacement in ESS, and it may suppress the remaining thyroid function and increase metabolic demands. Therefore, the focus is on the underlying condition.

The prognosis for ESS is directly related to the severity and reversibility of the underlying disease. In general, the presence of ESS indicates a more severe illness and is associated with a poorer prognosis compared to patients with normal thyroid function. Studies in dogs have shown that low TT4 and fT4 concentrations are associated with increased mortality in critically ill patients. However, if the underlying disease is treatable and the patient recovers, thyroid hormone levels typically return to normal. The prognosis is guarded to poor in cases of severe sepsis or multiple organ dysfunction, but more favorable in cases of mild to moderate illness. Serial monitoring of thyroid function may provide prognostic information, as normalization of thyroid hormones is associated with recovery.

Follow-up for ESS involves monitoring the underlying disease and re-evaluating thyroid function after recovery. Thyroid hormone levels should be rechecked 4-8 weeks after resolution of the illness to confirm normalization. If the patient remains clinically hypothyroid after recovery, further testing may be needed to rule out primary hypothyroidism. In patients with chronic diseases, periodic monitoring of thyroid function may be indicated, but routine testing is not recommended unless clinical signs suggest hypothyroidism. The frequency of follow-up depends on the underlying disease and the patient's response to treatment.

Pearls: (1) Always consider ESS in any critically ill patient with low thyroid hormone levels; do not immediately diagnose hypothyroidism. (2) Use fT4 by equilibrium dialysis and TSH to differentiate ESS from primary hypothyroidism. (3) Treat the underlying disease, not the thyroid hormone levels. (4) In cats, be cautious: hyperthyroidism can coexist with non-thyroidal illness, and thyroid hormone levels may be misleading. (5) Recheck thyroid function after recovery to confirm normalization. Pitfalls: (1) Administering thyroid hormone supplementation in ESS can be harmful and is not recommended. (2) Interpreting thyroid tests without considering the clinical context can lead to misdiagnosis. (3) Using total T4 alone is insufficient; fT4 and TSH are necessary. (4) Failing to consider drug effects on thyroid function. (5) Overlooking the possibility of primary hypothyroidism in a sick patient, especially if TSH is elevated.

There are no specific drug protocols for ESS. Treatment is directed at the underlying disease. However, if the patient is receiving drugs that suppress thyroid function, such as glucocorticoids (e.g., prednisone at 0.5-2 mg/kg/day PO, tapering), phenobarbital (2.5-5 mg/kg PO q12h), or sulfonamides (e.g., trimethoprim-sulfamethoxazole at 15-30 mg/kg PO q12h), these should be adjusted or discontinued if possible. Supportive care may include intravenous fluids (e.g., lactated Ringer's solution at 40-60 mL/kg/day for dogs, 30-50 mL/kg/day for cats, adjusted based on hydration status), nutritional support (e.g., enteral feeding via nasogastric tube), and management of organ dysfunction. For example, in sepsis, antibiotics (e.g., ampicillin 20 mg/kg IV q8h, enrofloxacin 5-10 mg/kg IV q24h) and vasopressors (e.g., norepinephrine CRI at 0.05-0.5 mcg/kg/min) may be used. In heart failure, diuretics (e.g., furosemide 1-4 mg/kg IV or PO q8-12h) and pimobendan (0.25 mg/kg PO q12h) may be indicated. Always refer to Plumb's Veterinary Drug Handbook for specific dosing and adjustments.

Several studies have characterized ESS in dogs and cats. A landmark study by Kantrowitz et al. (2001) evaluated thyroid function in critically ill dogs and found that low TT4 and fT4 were associated with increased mortality. Another study by Mooney et al. (2008) in cats with chronic kidney disease showed that low fT4 was common and correlated with disease severity. Consensus guidelines from the ACVIM (2018) on hypothyroidism in dogs emphasize the importance of distinguishing ESS from primary hypothyroidism. A meta-analysis by Scott-Moncrieff (2015) concluded that thyroid hormone supplementation is not beneficial in ESS and may be harmful. The use of fT4 by equilibrium dialysis and TSH is recommended as the most reliable diagnostic approach. Overall, the literature supports the concept that ESS is an adaptive response to illness, and treatment should focus on the underlying disease.